Evidence map›Paper›PMID 27673428›Full record

ArticleJournal of neurotrauma2017

High-Mobility Group Box 1 (HMGB1) Is Elevated Systemically in Persons with Acute or Chronic Traumatic Spinal Cord Injury.

Angelos Papatheodorou, Adam Stein, Matthew Bank, Cristina P Sison, Katie Gibbs, Peter Davies, Ona Bloom

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurotrauma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Angelos Papatheodorou1 Department of Autoimmune and Musculoskeletal Disorders, North Shore University Hospital , Northwell Health, Manhasset, New York.
Adam Stein2 Department of Physical Medicine and Rehabilitation, North Shore University Hospital , Northwell Health, Manhasset, New York.
Matthew Bank3 Department of Surgery, North Shore University Hospital , Northwell Health, Manhasset, New York.
Cristina P Sison4 Department of Molecular Medicine, Hofstra Northwell School of Medicine, North Shore University Hospital , Northwell Health, Manhasset, New York.
Katie Gibbs2 Department of Physical Medicine and Rehabilitation, North Shore University Hospital , Northwell Health, Manhasset, New York.
Peter Davies5 Litwin-Zucker Research Center for the Study of Alzheimer's Disease, the Feinstein Institute for Medical Research, North Shore University Hospital , Northwell Health, Manhasset, New York.
Ona Bloom1 Department of Autoimmune and Musculoskeletal Disorders, North Shore University Hospital , Northwell Health, Manhasset, New York.
Northwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation in traumatic spinal cord injury (SCI) has been proposed to promote damage acutely and oppose functional recovery chronically. However, we do not yet understand the signals that initiate or prolong inflammation in persons with SCI. High-Mobility Group Box 1 (HMGB1) is a potent systemic inflammatory cytokine-or damage-associated molecular pattern molecule (DAMP)-studied in a variety of clinical settings. It is elevated in pre-clinical models of traumatic spinal cord injury (SCI), where it promotes secondary injury, and strategies that block HMGB1 improve functional recovery. To investigate the potential translational relevance of these observations, we measured HMGB1 in plasma from adults with acute (≤ 1 week post-SCI, n = 16) or chronic (≥ 1 year post-SCI, n = 47) SCI. Plasma from uninjured persons (n = 51) served as controls for comparison. In persons with acute SCI, average HMGB1 levels were significantly elevated within 0-3 days post-injury (6.00 ± 1.8 ng/mL, mean ± standard error of the mean [SEM]) or 4-7 (6.26 ± 1.3 ng/mL, mean ± SEM), compared with controls (1.26 ± 0.24 ng/mL, mean ± SEM; p ≤ 0.001 and p ≤ 0.01, respectively). In persons with chronic SCI who were injured for 15 ± 1.5 years (mean ± SEM), HMGB1 also was significantly elevated, compared with uninjured persons (3.7 ± 0.69 vs. 1.26 ± 0.24 ng/mL, mean ± SEM; p ≤ 0.0001). Together, these data suggest that HMGB1 may be a common, early, and persistent danger signal promoting inflammation in individuals with SCI.

Indexed as

Acute DiseaseAdultAgedAged, 80 and overBiomarkersCervical VertebraeChronic DiseaseFemaleHMGB1 ProteinHumansMaleMiddle AgedSpinal Cord InjuriesThoracic VertebraeYoung AdultBiomarkersHMGB1 ProteinHMGB1 protein, humandamage-associated molecular patternhigh mobility group box 1inflammationspinal cord injury

Identifiers

PMID27673428
PMCPMC6436020
OpenAlexW2545762313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.